XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.23.3

INVESTMENT IN EQUITY SECURITIES | 9 Months Ended
--- | ---
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract] |
INVESTMENT IN EQUITY SECURITIES | INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following:
| September 30, 2023 |  | December 31, 2022
Equity Method Investments: |  |  |
BTY | $ | 31,665 |  |  | $ | 31,490 |
Sonmol | 4,621 |  |  | 4,997 |
Desotec GmbH | 859 |  |  | 863 |
Other Investments: |  |  |
PureCycle | 1,532 |  |  | 5,297 |
YAT | 5,204 |  |  | 5,508 |
Loop | 2,894 |  |  | 2,894 |
Others | 1,247 |  |  | 1,259 |
| $ | 48,022 |  |  | $ | 52,308 |
Equity Method Investments BTY On January 1, 2020, we acquired 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the nine months ended September 30, 2023 and September 30, 2022, Aptar had purchases of $10.7 million and $7.2 million, respectively, from BTY. As of September 30, 2023 and December 31, 2022, approximately $2.1 million and $1.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets. Sonmol On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In November 2020, we increased the value of the PureCycle investment by $3.1 million based on observable price changes. In March 2021, PureCycle was purchased by a special purpose acquisition company and was subsequently listed on Nasdaq under the ticker PCT. At that time, our investment in PureCycle was converted into shares of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. We have sold the following PCT shares related to the PureCycle investment:
| Shares Sold |  | Proceeds |  | Realized Gain
March 2022 | 107,600 |  | $ | 1,088 |  |  | $ | 841 |
August 2022 | 50,000 |  | $ | 511 |  |  | $ | 372 |
July 2023 | 248,859 |  | $ | 2,659 |  |  | $ | 1,968 |
August 2023 | 261,590 |  | $ | 2,945 |  |  | $ | 2,220 |
For the three and nine months ended September 30, 2023 and 2022, we recorded the following net investment gain or loss on our investment in PureCycle:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Net investment (loss) gain | $ | (1,240) |  |  | $ | 649 |  |  | $ | 1,839 |  |  | $ | (1,084) |
On July 7, 2021, we invested approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. There were no indications of impairment noted in the nine months ended September 30, 2023 related to these investments. In March 2022, we recorded a $1.5 million expected credit loss reserve against the outstanding note receivable from one of our venture investments (Kali Care) as a result of a proposed sale of such business.

X
- Definition The entire disclosure for equity method and other investments. + References No definition available. + Details
Name: | atr_EquityMethodAndOtherInvestmentsTextBlock
Namespace Prefix: | atr_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration